Compare ImmunityBio Inc. Common Stock (IBRX) vs National Grid Transco PLC National Grid PLC (NEW) American Depositary Shares (NGG) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
ImmunityBio Inc. Common Stock vs National Grid Transco PLC National Grid PLC (NEW) American Depositary Shares — how do they compare? ImmunityBio Inc. Common Stock trades at $10.23 (market cap $10.50B), while National Grid Transco PLC National Grid PLC (NEW) American Depositary Shares trades at $79.45 (market cap $78.99B). The key difference: National Grid Transco PLC National Grid PLC (NEW) American Depositary Shares is far larger — about 7.5× ImmunityBio Inc. Common Stock's market cap, and National Grid Transco PLC National Grid PLC (NEW) American Depositary Shares pays a 4.13% dividend while ImmunityBio Inc. Common Stock pays none. Which is the better fit depends on your goals.
| IBRX | NGG | |
|---|---|---|
Market Cap | $10.50B | $78.99B |
Volume | 30,068,214 | 740,402 |
Sector | Health | Utilities |
52-Week High | $11.55 | $93.93 |
52-Week Low | $1.98 | $73.54 |
Typical Hold Time | 6 Days | — |
Enterprise Value | $10.96B | $137.22B |
Dividend Yield | — | 4.13% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ImmunityBio (IBRX) trades at $9.80, down 3.16% on the day, amid a bullish technical setup and strong analyst support. The company reported revenue growth to $166 million in 2026 but remains deeply unprofitable with a net loss of $992 million. Recent FDA approval expansion for ANKTIVA in bladder cancer and high-profile executive appointments signal operational momentum, though cash burn remains a concern with negative operating cash flow.
Outlook is cautiously optimistic given the unanimous buy ratings and regulatory milestones, but investment carries high risk due to persistent losses, heavy reliance on financing, and competitive pressures. The stock's trajectory hinges on successful commercialization and pipeline execution to achieve profitability.
National Grid (NGG) trades at $78.23, up 1.44% on the day, with a market cap of approximately $48.3 billion. The stock shows stable technicals near its consensus price target of $79.25. Fundamentally, it maintains strong profitability with an 18.32% net income margin and has beaten EPS estimates in recent quarters. Recent news highlights institutional buying and a focus on grid innovation, including AI adoption.
Outlook is cautiously positive with upside to the high target of $85.50, supported by earnings momentum and strategic investments. Risks include high debt levels and regulatory pressures. Analyst consensus leans buy (55%), but hold ratings reflect concerns over capital intensity and macroeconomic sensitivity.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About ImmunityBio Inc. Common Stock
ImmunityBio develops immune-based therapies for cancer and infectious diseases. Its programs are designed to activate and strengthen the body’s immune response.
Read more on IBRX →About National Grid Transco PLC National Grid PLC (NEW) American Depositary Shares
National Grid plc is a British utility company that owns and operates electricity and gas transmission networks in Great Britain, and through its US Regulated business, operates electricity and gas transmission and distribution networks serving customers in New York and Massachusetts. Its shares trade on the NYSE as American Depositary Shares under the ticker NGG.
Read more on NGG →
